title: The context of blood vessels and response to VEGF-targeted therapy.
abstract: Although therapy directed against VEGF has produced clinical benefit, an understanding of responsive tumor characteristics is lacking. Blood vessel location relative to tumor cells and stromal factors may influence tumor susceptibility to VEGF-targeted therapy. Clinical validation of this potential biomarker is needed to influence clinical practice.
authors.affiliation: Author's Affiliation: Department of Solid Tumor Oncology, Lerner College of Medicine, Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, Cleveland, Ohio.
authors.forename: Brian I
authors.initials: BI
authors.lastname: Rini
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D017154:Stromal Cells / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab